Search company, investor...
Search
Biosplice Therapeutics company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

biosplice.com

Founded Year

2008

Stage

Series B | Alive

Total Raised

$561.5M

Last Raised

$120M | 1 yr ago

About Biosplice Therapeutics

Biosplice Therapeutics is a clinical-stage biotechnology company pioneering therapeutics based on alternative pre-mRNA splicing for major diseases. Its scientific platform is based on biological discoveries that govern tissue specialization and enable it to selectively eliminate harmful proteins using small molecules. From the company's foundational discoveries in Wnt pathway modulation to unlocking the broad therapeutic potential of the CLK/DYRK target class, its focus is on the realization of new, potentially curative therapies for patients by selectively reprogramming cellular behavior.

Biosplice Therapeutics Headquarters Location

9360 Towne Centre Drive Suite 160

San Diego, California, 92121,

United States

858-926-2900

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Biosplice Therapeutics

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Biosplice Therapeutics in 2 CB Insights research briefs, most recently on Jul 6, 2022.

Expert Collections containing Biosplice Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Biosplice Therapeutics is included in 4 Expert Collections, including Unicorns- Billion Dollar Startups.

U

Unicorns- Billion Dollar Startups

1,187 items

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

R

Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Biosplice Therapeutics Patents

Biosplice Therapeutics has filed 117 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • G protein coupled receptors
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

7/27/2020

9/20/2022

Food additives, Excipients, Fluoroarenes, Amines, Metal halides

Grant

Application Date

7/27/2020

Grant Date

9/20/2022

Title

Related Topics

Food additives, Excipients, Fluoroarenes, Amines, Metal halides

Status

Grant

Latest Biosplice Therapeutics News

Jonathan Wygant Appointed Chief Accounting Officer at Veracyte

Apr 20, 2022

Jonathan Wygant Appointed Chief Accounting Officer at Veracyte New hire was vice president, controller and chief accounting officer at Alere. Jonathan Wygant. Image courtesy of Veracyte. Michael Barbella, Managing Editor04.20.22 Veracyte Inc.  has appointed Jonathan Wygant as chief accounting officer. He now oversees all aspects of the company’s global accounting operations, financial reporting and tax functions, and reports to Rebecca Chambers, Veracyte’s chief financial officer. “We are thrilled to welcome Jonathan to Veracyte,” said Chambers. “He brings a depth of expertise and experience leading accounting operations for a range of healthcare companies, including global organizations. As we advance our global strategic vision, his accounting leadership will be critical to ensuring our organization’s continued success.”   Wygant most recently served as corporate controller at Biosplice Therapeutics Inc. (formerly Samumed LLC), a clinical-stage biotechnology company. In this role, he led all finance, accounting and reporting functions within the company. Prior to that, Wygant was the chief financial officer at Cibus Global LLC, where he supervised the company’s financial operations. He also served as vice president, controller and chief accounting officer at Alere Inc., a point-of-care diagnostics company that was acquired by Abbott in 2016. Prior to that, Wygant held various leadership roles at CareFusion, including senior vice president, controller and chief accounting officer. Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, colon cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco. Related Content

Biosplice Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Biosplice Therapeutics Rank

  • When was Biosplice Therapeutics founded?

    Biosplice Therapeutics was founded in 2008.

  • Where is Biosplice Therapeutics's headquarters?

    Biosplice Therapeutics's headquarters is located at 9360 Towne Centre Drive, San Diego.

  • What is Biosplice Therapeutics's latest funding round?

    Biosplice Therapeutics's latest funding round is Series B.

  • How much did Biosplice Therapeutics raise?

    Biosplice Therapeutics raised a total of $561.5M.

  • Who are the investors of Biosplice Therapeutics?

    Investors of Biosplice Therapeutics include Sands Capital, Eventide Asset Management, aMoon Fund, SymBiosis, Verition Fund Management and 7 more.

  • Who are Biosplice Therapeutics's competitors?

    Competitors of Biosplice Therapeutics include Lubris BioPharma.

You May Also Like

L
Lubris BioPharma

Lubris BioPharma is a development-stage life science company producing and commercializing a recombinant version of the human protein, lubricin. Lubricin is expressed in numerous parts of the human body and plays an important role in protecting surfaces from damage and wear. Opinion leaders and clinicians worldwide are focusing their research efforts on using lubricin to improve the lives of millions of people with a host of unmet medical needs including dry eye, osteoarthritis, surgical adhesions, xerostomia, and pericarditis.

Oyster Point Pharma Logo
Oyster Point Pharma

Oyster Point Pharma (NASDAQ: OYST) is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of therapies to treat diseases with high unmet needs. The company's initial focus is to develop therapeutics to treat the signs and symptoms of Dry Eye Disease (DED) by stimulating the trigeminal parasympathetic pathway to activate the glands responsible for tear film production.

Aldeyra Therapeutics Logo
Aldeyra Therapeutics

Aldeyra Therapeutics, formerly Neuron Systems, is a biotechnology company focused primarily on the development of products to treat immune-mediated, inflammatory, orphan, and other diseases that are thought to be related to a naturally occurring toxic chemical species known as free aldehydes. The company discovered and is developing NS2, a product candidate that is designed to trap and allow for disposal of free aldehydes, for the treatment of Sjogren-Larsson Syndrome (SLS), a rare disease caused by mutations in an enzyme that metabolizes fatty aldehydes, and acute anterior uveitis, an inflammatory eye disease.

Bioventus Logo
Bioventus

Bioventus (NASDAQ: BVS) is an orthobiologics company that delivers clinically proven, cost-effective products that help people heal quickly and safely. The company has two product portfolios for orthobiologics, Bioventus Active Healing Therapies and Bioventus Surgical that make it a global leader in active orthopaedic healing.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.